Di Zhe Medicine disclosed a net loss of 345 million yuan in the half -year report of 2022

On August 25, Dazhe Pharmaceutical (Code: 688192.SH) released the 2022 semi -annual performance report.

From January 1, 2022-June 30, 2022, the company realized operating income of 0.0000 yuan, a year-on-year decrease of 100.00%, a net loss of 345 million yuan, a loss of 15.51%year-on-year losses, and the basic earnings per share was -0.85 yuan.

The company's industry is chemical pharmaceutical.

During the company's reporting period, the total assets at the end of the period were 24.01 billion yuan, and the operating profit was -345 million yuan. The net cash flow generated by operating activities was -280 million yuan.

Dzhe Pharmaceutical, the company's full name Dzhe (Jiangsu) Pharmaceutical Co., Ltd., was established on October 27, 2017. The current general manager Zhang Xiaolin, the main business is the research and development, production and sales of innovative drugs.

- END -